Financial Analysis: LeMaitre Vascular (NASDAQ:LMAT) & Solventum (NYSE:SOLV)

LeMaitre Vascular (NASDAQ:LMAT) and Solventum (NYSE:SOLV) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Profitability

This table compares LeMaitre Vascular and Solventum’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
LeMaitre Vascular	18.33%	12.41%	10.78%
Solventum	N/A	N/A	N/A

Insider and Institutional Ownership

84.6% of LeMaitre Vascular shares are owned by institutional investors. 10.8% of LeMaitre Vascular shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings for LeMaitre Vascular and Solventum, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LeMaitre Vascular	0	1	5	1	3.00
Solventum	1	7	0	0	1.88

LeMaitre Vascular currently has a consensus target price of $94.40, suggesting a potential upside of 3.03%. Solventum has a consensus target price of $58.25, suggesting a potential downside of 14.01%. Given LeMaitre Vascular’s stronger consensus rating and higher possible upside, research analysts plainly believe LeMaitre Vascular is more favorable than Solventum.

Earnings & Valuation

This table compares LeMaitre Vascular and Solventum”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LeMaitre Vascular	$205.62 million	10.00	$30.10 million	$1.51	60.68
Solventum	$8.25 billion	1.42	N/A	N/A	N/A

LeMaitre Vascular has higher earnings, but lower revenue than Solventum.

Summary

LeMaitre Vascular beats Solventum on 10 of the 11 factors compared between the two stocks.

About LeMaitre Vascular

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient’s body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota.